Sort
10,766 grants matching “checkpoint inhibitor”
Engineering Nanomaterials to Prime Immunity
$393,246James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2017 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$393,225Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
$393,195Hans Ragnar Widlund · Brigham And Women'S Hospital · R01 · FY2018 · CA
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$393,090Binfeng Lu · Hackensack University Medical Center · R01 · FY2023 · CA
Defining critical p53 therapeutic targets and mechanisms
$393,005Clodagh O'Shea · Salk Institute For Biological Studies · R01 · FY2010 · CA
Defining critical p53 therapeutic targets and mechanisms
$393,005Clodagh O'Shea · Salk Institute For Biological Studies · R01 · FY2009 · CA
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$392,929Ann Richmond · Vanderbilt University · R01 · FY2020 · CA
Immune Regulation of Lung Squamous Metastasis
$392,837Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$392,779Fumito Ito · University Of Southern California · R01 · FY2025 · CA
Immune Activating CAR-Modified Antigen Presenting Cells
$392,709Carl Deselm · Washington University · DP5 · FY2019 · OD
Discoidin Domain Receptor Tyrosine Kinase 2 in bladder cancer progression
$392,659Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$392,632Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
The role of extracellular matrix quality in the prediction of metastasis-induced skeletal fragility and response to immunotherapy
$392,617Stacyann R Bailey · University Of Massachusetts Amherst · R21 · FY2023 · CA
Core B: Animal Model and Immunotyping Core
$392,597Xiaoxia Li · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Core B: Animal Model and Immunotyping Core
$392,597Thaddeus S Stappenbeck · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Identification of REV-ERB inverse agonists for cancer immunotherapy
$392,550Laura A Solt · Scripps Florida · R01 · FY2021 · CA
T Cell Immunity in Giant Cell Arteritis
$392,500Cornelia M Weyand · Stanford University · R01 · FY2018 · HL
T Cell Immunity in Giant Cell Arteritis
$392,500Cornelia M Weyand · Stanford University · R01 · FY2020 · HL
T Cell Immunity in Giant Cell Arteritis
$392,500Cornelia M Weyand · Stanford University · R01 · FY2019 · HL
Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma
$392,485Athan Kuliopulos · Oasis Pharmaceuticals · R41 · FY2022 · CA
Reprogramming the Tumor Microenvironment in Ovarian Cancer
$392,449David D Schlaepfer · University Of California, San Diego · R01 · FY2024 · CA
Signal and Transcription Factor Network interactions in Head and Neck Cancer
$392,219Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2018 · DC
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$392,171Mark W Jackson · Case Western Reserve University · R01 · FY2024 · CA
Project 1: Siglec15 as a new target for lung cancer immunotherapy
$392,133David L Rimm · Yale University · P50 · FY2023 · CA
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
$392,077Ralph R Weichselbaum · University Of Chicago · R01 · FY2024 · CA